Founder of Raymond Fong Eye Care
Dr. Raymond Fong graduated from Harvard with honors. He then went to Cornell Medical School and completed his eye residency at the prestigious Manhattan Eye, Ear & Throat Hospital. He is a Board Certified Fellow of the American Academy of Ophthalmology. He is a Board Certified Fellow of the American Academy of Ophthalmology, and has personally performed over 45,000 cataract operations and over 20,000 LASIK surgeries, and over 45,000 other laser procedures. As an active participant in his community, he has been past President of the Chinese American Medical Society, as well present chairman of the Chinatown health Clinic Foundation, an organization dedicated to providing health care for poor and recent immigrants.
Dr. Fong has been consistently cited as one of the top doctors in THE BEST DOCTORS-NEW YORK METRO AREA (Published by Castle Connolly Medical Ltd., and available in most book store) since 1993 and has one of the largest cataract and LASIK practices in New York City. Dr. Fong is the director of New York Eye Surgical Center and Brooklyn Eye Surgery Center. He is also a co-founder and director of one of only five LASIK centers in the USA, and the only one in New York, to be designated a Novartis/Alcon Center of Excellence in LASIK.
Dr. Fong is recognized as a KOL (Key Opinion Leader) in his field. He is a consultant and/or speaker for many of the top surgical and pharmaceutical companies worldwide, including Alcon and Bausch & Lomb. He is also a principal investigator in many FDA trials. The FDA (United States Food and Drug Administration) is responsible for the testing of new medical and surgical treatments. By participation in these highly complex and important studies, he gains insight in how to integrate the latest trends and best treatments into his practice.
Publications & Presentations
- Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample. Robert Lehmann, Andrew Maxwell, David M Lubeck, Raymond Fong, Thomas R Walters, Anna Fakadej;Clin Ophthalmol. 20 April 2021 Volume 2021:15 Pages 1647—1657
- Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.Fong, R.,Silverstein, B. E.,Peace, J. H.,Williams, J. I.,Vittitow, J. L. ;J Cataract Refract Surg. 2018 Sep 09
- Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study.Modi, S. S.,Lehmann, R. P.,Walters, T. R.,Fong, R.,Christie, W. C.,Roel, L.,Nethery, D.,Sager, D.,Tsorbatzoglou, A.,Philipson, B.,Traverso, C. E.,Reiser, H.; J Cataract Refract Surg. 2013 Dec 19.
- Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial.Fong, R., Leitritz, M., Siou-Mermet, R., Erb, T.; Clin Ophthalmol. 2012.
